Intensive chemotherapy with or without autologous stem cell transplantation in myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML).
| Source . | Number of Patients . | Median Age (years) . | Induction Chemotherapy . | CR (%) . | Number of Patients Transplanted . | Outcome # . |
|---|---|---|---|---|---|---|
| #: Outcome: median duration in months or percentage at 2 years or 4 years | ||||||
| ##: 3 allogeneic BMT, 3 autologous stem cell transplantation | ||||||
| ###: Report on 79 patients transplanted in first CR | ||||||
| *: DFS and OS with or without fludarabine respectively | ||||||
| **: 65 patients without HLA-identical sibling donor | ||||||
| Abbreviations: CR, complete remission; A, cytarabine; Z, zorubicine; I, idarubicin; M, mitoxantrone; Q, quinine; E, etoposide; G-CSF, granulocyte colony-stimulating factor; DFS, disease-free survival; OS, overall survival; EFS, event-free survival; RAEB, refractory anemia with excess blasts; RAEBt, RAEB in transformation | ||||||
| Ossenkoppele 2004 30 | MDS 91 AML 43 | 65/69 | A + G-CSF + F | 68 | — | DFS 23/16% OS 39/24%* |
| Fenaux 1991 32 | MDS 31 sAML 16 | 54 | Z + A | 47 | — | DFS: 11 mo OS: 14 mo |
| De Witte 1995 33 | MDS 34 sAML 16 | 46 | I + A | 54 | — | DFS: 11 mo OS: 15 mo |
| Parker 1997 34 | MDS 13 sAML 3 | 44 | I + A + F + G-CSF | 63 | 6 ## | Too short follow-up |
| Estey 1997 35 | MDS 158 | 60 | I + A or F + A ± G-CSF | 65 | — (RAEB/RAEBt) | DFS : 5–12 mo |
| De Witte 1997 36 ### | MDS 19 sAML 60 | 39 | relapse: 64% | — 79 DFS: 34% OS: 39% | ||
| Wattel 1999 37 | MDS 37 sAML 46 | 45 | A + M ± Q | 51 | 24 | DFS: 29 mo OS: 33 mo |
| Oosterveld 2003 38 | MDS 91 sAML 28 | 47 | A + I + E | 54 | 32/65*** | EFS: 23* |
| Source . | Number of Patients . | Median Age (years) . | Induction Chemotherapy . | CR (%) . | Number of Patients Transplanted . | Outcome # . |
|---|---|---|---|---|---|---|
| #: Outcome: median duration in months or percentage at 2 years or 4 years | ||||||
| ##: 3 allogeneic BMT, 3 autologous stem cell transplantation | ||||||
| ###: Report on 79 patients transplanted in first CR | ||||||
| *: DFS and OS with or without fludarabine respectively | ||||||
| **: 65 patients without HLA-identical sibling donor | ||||||
| Abbreviations: CR, complete remission; A, cytarabine; Z, zorubicine; I, idarubicin; M, mitoxantrone; Q, quinine; E, etoposide; G-CSF, granulocyte colony-stimulating factor; DFS, disease-free survival; OS, overall survival; EFS, event-free survival; RAEB, refractory anemia with excess blasts; RAEBt, RAEB in transformation | ||||||
| Ossenkoppele 2004 30 | MDS 91 AML 43 | 65/69 | A + G-CSF + F | 68 | — | DFS 23/16% OS 39/24%* |
| Fenaux 1991 32 | MDS 31 sAML 16 | 54 | Z + A | 47 | — | DFS: 11 mo OS: 14 mo |
| De Witte 1995 33 | MDS 34 sAML 16 | 46 | I + A | 54 | — | DFS: 11 mo OS: 15 mo |
| Parker 1997 34 | MDS 13 sAML 3 | 44 | I + A + F + G-CSF | 63 | 6 ## | Too short follow-up |
| Estey 1997 35 | MDS 158 | 60 | I + A or F + A ± G-CSF | 65 | — (RAEB/RAEBt) | DFS : 5–12 mo |
| De Witte 1997 36 ### | MDS 19 sAML 60 | 39 | relapse: 64% | — 79 DFS: 34% OS: 39% | ||
| Wattel 1999 37 | MDS 37 sAML 46 | 45 | A + M ± Q | 51 | 24 | DFS: 29 mo OS: 33 mo |
| Oosterveld 2003 38 | MDS 91 sAML 28 | 47 | A + I + E | 54 | 32/65*** | EFS: 23* |